Meningococcal Vaccines Market Growth, Future Scope, Challenges, Opportunities 2030
According to MRFR analysis, Meningococcal
Vaccines Market has a demand for USD 172 Million. Further, the global
estimated supply in 2019 is expected to be 203 Million doses.
Despite broad and effective commitment from the global
health community in meningitis A (MENA) vaccination in the meningitis belt, low
manufacturing capacity and high prices across other meningococcal vaccine types
have hindered access to these vaccines over the past several years. A more
in-depth knowledge will benefit addressing these long-standing access issues
and the development of the WHO global roadmap for overcoming meningitis by
2030. This is expected to set goals for disease control and vaccination for
meningococcal meningitis on a global level.
Regional Analysis
Need for meningococcal vaccines is characterized by
significant use outside of routine immunization: subnational use, immunization
of special risk groups such as military personnel or travelers, private market
use, or recommended but not-reimbursed immunization. In 2019, in addition to
the 39 mostly HIC and meningitis belt countries that use meningococcal vaccines
in national immunization programs NIPs, 27 countries use meningococcal vaccines
only for special risk groups. National routine uses in 2019 accounts for
approximately 100 million doses across all countries except for China.
However, other countries in the African and Eastern
Mediterranean region have indicated interest in introducing a multivalent,
conjugate vaccine into routine National Immunization Program Schedule, but have
strived to access these vaccines due to the high price and limited
availability.
Further, in 2018, 3.2 million doses were available in the
Global stock, compared with 5 million doses that professionals forecast will be
needed each year in the future, with more C- and W-containing vaccines needed to
focus on the rising incidence of those serogroup globally.
Overall, demand for MenACWY conjugate is expected to
increase over the short- and mid-term, as HICs and MICs show a growing
inclination for immunization strategies targeting multiple serogroups and as
Hajj pilgrims increasingly use MenACWY conjugate due to withdrawal of
polysaccharide products.
Segmentation
The Global Meningococcal Vaccines Market has been segmented
based on treatment type and end-user. The market, based on treatment type, has
been divided into the meningococcal
conjugate vaccine, polysaccharide, and subcapsular vaccine. In terms of
end-user, the global meningococcal vaccines market has been segmented into
hospitals & clinics, research & academic institutes, and others.
Key Players
Some of the key players in the Global Meningococcal Vaccines
Market are Baxter International, Pfizer Inc., Novartis Pharmaceuticals Canada
Inc, Sanofi S.A., JN-International Medical Corporation, Biomed Pvt. Ltd., Serum
Institute of India Ltd., and GlaxoSmithKline among others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Comments
Post a Comment